anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
However, according to a 2014 AHRQ report, there have been no studies evaluating the effectiveness of any prescription opioid risk mitigation strategies. Furthermore, due to ambiguity in some of the CDCG recommendations and the challenging nature of the patient-provider opioid conversation, the success of the CDCG may hinge on the manner in which it is implemented in individual care settings. Thus it is unclear what the true effect of the CDCG will be. The investigators believe that for the CDCG to have the greatest likelihood of achieving its goals of improving prescription opioid safety without causing unintended effects (e.g. exacerbation of pain, disruption of other aspects of care), its recommendations will need to be skillfully communicated. Furthermore, because of this "human element"and other sources of variability, documenting the effectiveness of the CDCG will require standardization of implementation. The overarching plan for TOWER is to develop and test an algorithmic version of the CDCG tailored for a specific primary care setting, the HIV primary care clinic. This CDCG intervention incorporates communication and implementation strategies tailored for the HIV primary care setting, and enabled with technology (an app for use by patients and EMR tools for providers). Achieving this goal has involved soliciting input from the HIV community using the method of Public Deliberation (PD) in the setting of two Citizen' s Panels, each with \~22 HIV-infected participants and lasting one day; and using the information obtained from the deliberative process to inform the development of the CDCG intervention. The investigators now plan to test the CDCG intervention for feasibility.
Evidence from in vitro and animal models has identified the pulmonary toxicity of flavors in electronic cigarettes (ECIGs); however, less is known from epidemiological studies about the effects of flavors in the respiratory health. This study examined the longitudinal association between exposure to ECIGs flavors and nocturnal dry cough among ECIGs users. A secondary analysis of data from the Population Assessment of Tobacco and Health Study (2014-2019) was conducted. The study population included adults who provided information (n = 18,925) for a total of 38,638 observations. Weighted-incidence estimates and weighted- generalized estimating equation models were performed to assess unadjusted and adjusted associations. The weighted incidence proportion (WIP) of nocturnal dry cough was significantly higher among current (WIP:16.6%; 95%CI 10.5, 21.2) and former fruit flavored ECIGs users (WIP:16.6%; 95%CI 11.3, 21.9) as compared to non-ECIGs users (WIP:11.1%; 95%CI 10.6, 11.6). Current ECIGs users of fruit flavors showed 40% higher risk of reporting cough than non-ECIGs users (aRR:1.40, 95%CI 1.01, 1.94). Former ECIGs users of multiple flavors and other flavors had 300% and 66% higher risk to develop cough, respectively (aRR:3.33, 95%CI 1.51, 7.34 and aRR:1.66, 95%CI 1.0.9, 2.51), relative to non-ECIGs users. We observed a significantly higher risk of developing nocturnal dry cough in the past 12 months in current and former ECIGs users of fruit flavors and in former ECIGs users of multiple flavors. To the extent that cough may serve as an early indicator of respiratory inflammation and potential disease risk, the association between ECIGs use and cough raises potential concerns.
Dermatomyositis is a rare, autoimmune systemic disorder of unknown aetiology that presents as a constellation of clinical symptoms and signs primarily affecting skin and muscles. Patients with dermatomyositis can present with rare "non-canonical" manifestations. Focal or generalised oedema is an infrequent and often overlooked symptom of the disease, while spontaneous intramuscular haemorrhage is an even rarer and under-recognised, life-threatening complication that constitutes a medical emergency for clinical physicians. There are no known predisposing factors able to predict which patients will develop this complication and specific instructions considering treatment approach are currently lacking. Herein, we present a case of a patient with dermatomyositis complicated by both anasarca and spontaneous intramuscular haemorrhage. In order to raise awareness and timely diagnosis of such patients, we provide a review of the relevant literature and of the cases reported this far.
Following a screening evaluation, participants will receive two infusions of tocilizumab, one at baseline and another at week 4 of the study. All subjects will receive a 4 mg/kg infusion of tocilizumab, the recommended starting dose for adults with rheumatoid arthritis.
BACKGROUND/OBJECTIVES: The outcomes of patients with intraepithelial neoplasia at the pancreatic transection margin after pancreatic cancer surgery remain unclear. We evaluated the clinical impact of pancreatic transection margin status.
METHODS: This retrospective observational study included 171 patients who underwent surgery for pancreatic ductal adenocarcinoma between January 2008 and December 2019. Patients were classified into three groups: negative pancreatic transection margin (group N), positive low-grade (group L), and positive high-grade (group H) intraepithelial neoplasia. The clinicopathological findings and prognoses were analyzed for each group.
RESULTS: There were 140, 14, and 9 patients in groups N, L, and H, respectively. The median age was significantly higher in group H (p = 0.035). There were no significant differences in male ratio, preoperative chemotherapy administration rate, pretreatment tumor markers, operative procedure, operative time, or blood loss. Overall survival and recurrence-free survival were not significantly different; however, the cumulative risk of recurrence in the remnant pancreas was significantly higher in group H (p = 0.018).
CONCLUSIONS: Intraepithelial neoplasia at the pancreatic transection margin did not affect overall/recurrence-free survival. As patients with high-grade intraepithelial neoplasia at the pancreatic transection margin have an increased risk of recurrence in the remnant pancreas, careful postoperative follow-up is required.
The invention discloses a recombinant protein, which is the recombinant protein of the following a) or b): a) The amino acid sequence is a recombinant protein of SEQ ID No. 2; b) The recombinant protein which can code for the activity of the monkey pox antigen is obtained by substituting and/or deleting and/or adding one or more amino acid residues in the amino acid sequence shown in SEQ ID No. 2. The invention screens proper recombinant virus subunit vaccine from EEV and IMV surface antigen, and the toxicity attack protection rate of immune group shows that the bigeminal fusion recombinant protein can generate 100% immunity protection rate. Is a high-efficiency and safe technical means, and solves the problems of unstable protection effect, easy secondary infection, strong toxicity and the like of the existing inactivated vaccine and the existing attenuated vaccine. The recombinant protein and the biological material can be used for preparing a monkey pox virus subunit vaccine and can be applied to the prevention of monkey pox.
Evidence has shown that trunk performance is related to measures of balance, gait and functional ability. Yet, several aspects of trunk performance such as sitting balance, trunk muscle strength, selective trunk movements and trunk position sense are impaired after stroke. This implies that impaired trunk performance will inevitably lead to impaired postural control during activities performed while standing and walking. Nonetheless, the interaction between increased trunk performance and improvements in activities performed while standing and walking is not evident. It has previously been stated that therapy primarily induces treatment effects on the abilities at which training is specifically aimed. However, previous research has shown that additional trunk exercises improve not only trunk performance but also standing balance and mobility. Yet, the clinical outcome measures used in previous studies are not suitable to explore the relationship between trunk and gait performance and cannot explain the underlying mechanisms of the therapeutic effects. Since studies using sensitive motion analyses to investigate trunk biomechanics during gait are sparse in both healthy subjects and subjects with stroke. Data will be gathered by a Vicon analysis system (©Vicon Motion Systems Ltd., London, UK) with a measuring frequency of 100 Hz and eight infrared automated cameras (Vicon T10 cameras, 100 fps, 1 Megapixel) measured the 3D coordinates of the reflective markers. In addition, initial contact and toe off were defined based on the ankle trajectories of the reflective markers together with 3 AMTI type OR 6-7 force plates (1000 fps, 46x50x8 cm) and 1 AccuGait® (1000 fps) force plate recordings. Reflective motion trackers were attached to anatomical landmarks on the participant's body according to the standard Plug-In-Gait model. Furthermore, a 16 channel telemetric wireless EMG system (Arion Zerowire) will measure muscle activity.
PURPOSE: To obtain a fine particle useful for means for administering a biologically active substance to an egg of birds before hatching without requiring application of a sterilizing means, and capable of suppressing the fear of damaging growing embryo in the egg to minimum. CONSTITUTION: This fine particle is suitable for the use by an injection to an egg having an outer coat and an inner coat and having a liquid between the coats without a part of the egg forming an air chamber with the outer and inner coats, has a size and a density capable of being transferred through the liquid between the both coats to the end of the egg in the opposite side. The fine particle has the density at least same as that of the liquid between the coats, and <=500 μm, preferably 125-250 μm average size. A biologically active material (e.g. a growth hormone releasing factor) is immobilized to the fine particle and injected to the air-tight part of the egg placed so that the air-tight part may be present in the upper part.  A matrix for the fine particle is preferably a polyester selected from polylactide polymer, polyglycoside polymer and lactic acid-glycolic acid copolymer.
OBJECTIVE: Cancer-related fatigue (CRF) has been considered the biggest influencing factor for cancer patients after surgery. This study aimed to develop and validate a nomogram for severe cancer-related fatigue (CRF) patients with cervical cancer (CC).
METHODS: A cross-sectional study was conducted to develop and validate a nomogram (building set = 196; validation set = 88) in the Department of Obstetrics and Gynecology of a Class III hospital in Shenyang, Liaoning Province. We adopted the questionnaire method, including the Cancer Fatigue Scale (CFS), Medical Uncertainty in Illness Scale (MUIS), Medical Coping Modes Questionnaire (MCMQ), Multidimensional Scale of Perceived Social Support (MSPSS), and Sense of Coherence-13 (SOC-13). Binary logistic regression was used to test the risk factors of CRF. The R4.1.2 software was used to develop and validate the nomogram, including Bootstrap resampling method, the ability of Area Under Curve (AUC), Concordance Index (C-Index), Hosmer Lemeshow goodness of fit test, Receiver Operating Characteristic (ROC) curve, Calibration calibration curve, and Decision Curve Analysis curve (DCA).
RESULTS: The regression equation was Logit(P) = 1.276-0.947 Monthly income + 0.989 Long-term passive smoking - 0.952 Physical exercise + 1.512 Diagnosis type + 1.040 Coping style - 0.726 Perceived Social Support - 2.350 Sense of Coherence. The C-Index of the nomogram was 0.921 (95% CI: 0.877∼0.958). The ROC curve showed the sensitivity of the nomogram was 0.821, the specificity was 0.900, and the accuracy was 0.857. AUC was 0.916 (95% CI: 0.876∼0.957). The calibration showed that the predicted probability of the nomogram fitted well with the actual probability. The DCA curve showed when the prediction probability was greater than about 10%, the benefit of the nomogram was positive. The results in the validation group were similar.
CONCLUSION: This nomogram had good identifiability, accuracy and clinical practicality, and could be used as a prediction and evaluation tool for severe cases of clinical patients with CC.
Consumption of a portion of seaweed powder in a capsule equivalent to 200 µg of iodine (0.25g) consumed with 450 mL water. Collection of urine for 36 hours following ingestion. Collection of one fecal sample up to 24 hours following ingestion.
Attention Guidance Augmentation. The attention guidance condition consists of two unique components in addition to the standard iExposure intervention: (1) the intervention rationale will include information about the importance of visually attending to the faces of the audience; (2) participants will be given a target audience member to focus their gaze on during each impromptu response. They will be told that they should look at and focus on the target audience member for the whole response. In each progressive session the number of trials where the participant is directed to focus on an uninterested audience member will increase.
A major depressive episode may be the initial presentation of Bipolar Disorder. It is generally believed (though not established in controlled trials) that treating such an episode with an antidepressant alone may increase the likelihood of precipitation of a mixed/manic episode in patients at risk for Bipolar Disorder. Whether any of the symptoms described for clinical worsening and suicide risk represent such a conversion is unknown. However, prior to initiating treatment with an antidepressant, patients with depressive symptoms should be adequately screened to determine if they are at risk for Bipolar Disorder; such screening should include a detailed psychiatric history, including a family history of suicide, Bipolar Disorder, and depression. It should be noted that fluoxetine tablet is not indicated for the treatment of depressive episodes associated with Bipolar I Disorder.

No patients treated with fluoxetine tablet in 4 PMDD clinical trials (N = 415) reported mania/hypomania. In all US fluoxetine clinical trials for conditions other than PMDD, 0.7% of 10,782 patients reported mania/hypomania. Activation of mania/hypomania may occur with medications used to treat depression, especially in patients predisposed to Bipolar I Disorder.
Participants with cervical cancer and SCCHN received MEDI4736 10 mg/kg IV infusion Q2W at an infusion rate of approximately 60 minutes followed by ADXS11-001 1×10\^9 CFU IV infusion Q4W at an infusion rate of approximately 60 minutes. Treatment cycles were 8-week in duration and participants were to continue therapy for up to 1 year or until documented progression, unacceptable toxicity, withdrawal of consent, or other treatment discontinuation criteria were met.
This study will initially evaluate an FDA approved investigational dosage and will measure the blood levels over time while BPI is being infused through a vein to see if the dose is potentially enough to obtain the desired effect. The drug will be started within 8 hours of burn injury and continued for 48 hours. Patients will be followed on admission and through infusion in the Burn ICU where they will be monitored by ICU standards. They will be seen regularly thereafter on post-burn days 1, 2, 3, 4, 7, 14 and 28 days while in the hospital. If the patient is discharged prior to the 28 day evaluation, they will be evaluated on or around the 28th day in the burn clinic. A blood sample will be obtained to look for potential genetic markers that may increase a burn patients' risk to develop infection in the post burn period.
Described herein is an oral pharmaceutical composition comprising methotrexate which has a sustained release profile. Measured by the USP type II dissolution apparatus (paddle method) the composition exhibits a release profile with more than about 80 % of the methotrexate released within 8-18 hours, see the dissolution profiles of formulation P2, P4, P5, and P6 at figure 6. Further the composition comprises a hydrophilic polymer as for example Carbopol and gas generating agents in form of carbonate salt or bicarbonate salt. Consequently, the composition will swell and float in the stomach, which delays the passage of the composition through the pylorus and increases gastrointestinal residence. In addition methods of treating or preventing diseases as for example autoimmune diseases and cancer by treatment with the oral sustained release methotrexate composition are described. In some embodiments, these approaches improve the pharmacotherapeutic performance of methotrexate therapy.
Erlotinib hydrochloride and quinacrine dihydrochloride. The next 12 patients will enter into the second part of this study.
The invention discloses an application of shRNA for inhibiting SOX30 gene expression in preparing a medicine for treating triple negative breast cancer. The nucleotide sequence of the shRNA for inhibiting SOX30 gene expression is shown as SEQ ID NO.1 or SEQ ID NO. 2. According to the invention, based on the mRNA sequence of the SOX30 gene, two shRNAs are designed and screened, so that the expression of the SOX30 gene in triple negative breast cancer cells can be obviously reduced. The expression of SOX30 genes can be effectively regulated and interfered after constructing corresponding shRNA lentiviruses and then infecting triple negative breast cancer HCC38 cells by using the lentiviruses containing target shRNA sequences, so that the invasion and/or migration capacity of the triple negative breast cancer cells can be inhibited; therefore, the SOX30 gene targeted shRNA has the capability of reducing the expression of SOX30 and effectively inhibiting invasion and/or migration of triple negative breast cancer cells. The invention provides a new gene target spot and medicine for treating triple negative breast cancer, and has high clinical practical application value.
Resistance strength training for Resistance exercise and aimed at promoting the greatest hypertrophy response(65% of 1 repetition maximum and repeated up to 15 times). Resistance exercise intervention five times a week, one hour each time,for three months.
Nitrate ions liberated during metabolism of isosorbide dinitrate can oxidize hemoglobin into methemoglobin. Even in patients totally without cytochrome b 5 reductase activity, however, and even assuming that the nitrate moieties of isosorbide dinitrate are quantitatively applied to oxidation of hemoglobin, about 1 mg/kg of isosorbide dinitrate should be required before any of these patients manifests clinically significant (≥10%) methemoglobinemia. In patients with normal reductase function, significant production of methemoglobin should require even larger doses of isosorbide dinitrate. In one study in which 36 patients received 2 to 4 weeks of continuous nitroglycerin therapy at 3.1 to 4.4 mg/hr (equivalent, in total administered dose of nitrate ions, to 4.8 to 6.9 mg of bioavailable isosorbide dinitrate per hour), the average methemoglobin level measured was 0.2%; this was comparable to that observed in parallel patients who received placebo. 

Notwithstanding these observations, there are case reports of significant methemoglobinemia in association with moderate overdoses of organic nitrates. None of the affected patients had been thought to be unusually susceptible.

Methemoglobin levels are available from most clinical laboratories. The diagnosis should be suspected in patients who exhibit signs of impaired oxygen delivery despite adequate cardiac output and adequate arterial pO 2. Classically, methemoglobinemic blood is described as chocolate brown, without color change on exposure to air. 

When methemoglobinemia is diagnosed, the treatment of choice is methylene blue, 1 to 2 mg/kg intravenously.
The invention discloses an improved miRNA-disease association prediction method based on collaborative filtering. The miRNA-disease prediction problem can be seen as a recommended repair problem. Based on the bipartite network of known miRNA disease associations, it is recommended to use mirnas according to their known preferences for the associated diseases and vice versa. The importance matrix SIGd measuring one disease to another disease is first defined and calculated. The scores for SIGd (d (i), d (j)) were higher when disease d (i) was considered more important. SIGr was similarly defined and calculated to measure the importance of both mirnas. And secondly, the scores are calculated using the saliency matrix and the similarity matrix as weights. The similarity matrix is defined to represent the similarity between mirnas or diseases, and the final score for a miRNA-disease association is the sum of the score of a miRNA for a disease and the score of the disease for a miRNA. The invention realizes higher prediction precision.
FIELD: clinical medicine, pediatrics. SUBSTANCE: method involves the use of succinic acid at dose 100-200 mg per os as a single dose, once per a day, for 10-14 days. Blood plasma, red cells and urine were examined. Succinic acid promotes decrease of peroxidation degree, urine oxalate excretion, membrane damage, i. e . decreases toxic effect of vitamin Dhigh doses in children with vitamin D-resistant rickets. EFFECT: enhanced effectiveness of treatment.
The present invention provides a method for reinforcing human hair using artificial hair. According to the present invention, the method for reinforcing human hair using artificial hair includes: a step of selecting human hair to be reinforced; a step of forming a knot by binding artificial hair for reinforcing human hair and the human hair selected; a step of applying a perm reducing agent to the knot; and a step of rinsing the perm reducing agent for 2 to 5 minutes after applying the perm reducing agent. According to the present invention, the method for reinforcing human hair using artificial hair provides a very flexible curvature corresponding to the knot while cysteine combination of the hair is broken and recombined in the knot by the perm reducing agent. Also, since the surface of the hair is rough, the position of the knot is prevented from being moved or the knot is prevented from becoming untied as the hair slips. So, the method for reinforcing human hair using artificial hair can strongly maintain the binding force of the knot for long time. Therefore, there is no need to excessively twist the hair or to form the knot in a complex pattern on purpose, to reinforce the binding force of the knot, and the method for reinforcing human hair using artificial hair forms only a knot in a relatively simple pattern. So, the method for reinforcing human hair using artificial hair can largely reduce the total procedure time. Also, since a complex knot is not formed, the existing knot is easily untied when performing the procedure again. So, the method for reinforcing human hair using artificial hair can largely reduce the time required for performing the procedure again.